Merus N.V. CS (MRUS)

$54.51 +2.18 (4.17%)
Market Cap 3.62B
Revenue (ttm) 36.13M
Net Income (ttm) -215.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -595.99%
Debt to Equity Ratio 0.00
Volume 1,303,700
Avg Vol 1,249,748
Day's Range N/A - N/A
Shares Out 69.21M
Stochastic %K 83%
Beta 1.00
Analysts Strong Sell
Price Target $90.14

Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cel...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 30 253 8800
Address:
Uppsalalaan 17, 3rd & 4th floor, Utrecht, Netherlands
Llamalamb2921
Llamalamb2921 Jul. 8 at 12:35 PM
$MRUS Shareholders here need to look at $PDSB. Market cap is $56M vs nearly $4B for Merus. PDSB is the cleanest play for the lucrative and growing HPV16+ population. Versamune technology also lends itself to other immunotherapy antigens like MUC-1 as well as excellent study results in Universal Flu vaccine hopefully going into human trials soon.
1 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 10:00 AM
BMO Capital updates rating for Merus ( $MRUS ) to Outperform, target set at 91 → 96.
0 · Reply
YasirTrades
YasirTrades Jun. 20 at 12:05 AM
GLMD The risk/reward is insane. Under $2. Cash-rich. No debt. $12+ book. GLP-1 & fibrosis catalysts ahead. No fluff, just facts. $EPIX $ADIL $MRUS $MBOT $SYTA 🚨🚨🚨🚨
0 · Reply
Bionoobbb
Bionoobbb Jun. 14 at 4:11 AM
$MRUS $PDSB Merus 🔹 Target Population: Merus is conducting clinical trials targeting first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). These trials include both HPV-positive and HPV-negative patients. The main therapy is a combination of petosemtamab with Keytruda. 🔹 Current Status: • These trials require patients to be PD-1–naïve (i.e., they must not have received prior anti–PD-1 therapy). • With Keytruda now moving into perioperative use in early-stage disease, a growing portion of patients will receive Keytruda earlier in their treatment journey. • When these patients eventually experience recurrence, they will no longer be eligible for Merus trials due to prior PD-1 exposure. 🔹 Conclusion: ❌ This creates significant near- and long-term negative impact. As Keytruda use expands in early settings, Merus’s addressable patient pool continues to shrink.
1 · Reply
Bionoobbb
Bionoobbb Jun. 13 at 2:00 PM
$PDSB $MRUS @DubK FDA has approved $MRK keytruda in neoadjuvant which will reduce the patient pool for MRUS & $BCAX Smaller Patient Pool • Merck’s Keytruda just got approved for (neoadjuvant use) • Since Keytruda is now approved and proven, doctors may choose it over joining a new trial for an experimental drug. • Result: Fewer patients may join Merus’ trial, making it harder for them to prove their drug works or to sell it later.
0 · Reply
fezziwig2018
fezziwig2018 Jun. 12 at 6:33 PM
“HPV16 & HPV18 are the main high-risk types responsible for both cervical and HNSCC, with HPV16 accounting for 90% of HPV+ OPSCC” https://mdpi.com/1422-0067/23/7/3483 $PDSB targets 16-by far more/more difficult cases of head/neck ca vs $MRUS (strains of 8 pts included in last data omitted) https://www.mdpi.com/1422-0067/23/7/3483
0 · Reply
bmess
bmess Jun. 6 at 7:15 PM
$MRUS not very smart
0 · Reply
OptionsSean
OptionsSean Jun. 6 at 4:56 PM
The market tipped it's hand earlier this week in $MRUS. I'm buying this dip:
1 · Reply
Ontherag
Ontherag Jun. 6 at 2:55 PM
$MRUS Hey Bill, ask KevinHarrington what he thinks. Thanks.
0 · Reply
Llamalamb2921
Llamalamb2921 Jun. 6 at 11:03 AM
$MRUS I strongly recommend that your CEO Bill Lundberg speak with Frank at $PDSB to learn specifically about HPV16+ HNSCC. If not Frank, he can speak to other experts in the field regarding HPV16+ cancers and how they differ from other subsets of HPV+ HNSCC. Bill may need to temper his enthusiasm a bit and give some credit to the people at PDSB with their $65M market cap. He touches his heart a lot and seems to care very much for patients. Would he choose his drug trial for a loved one with an HPV16+ malignancy? Stick to HPV negative tumors Bill. There is enough room in the space for both companies to be successful.
0 · Reply
Latest News on MRUS
One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed

Jul 3, 2025, 3:00 AM EDT - 6 days ago

One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

Jun 11, 2025, 9:42 AM EDT - 4 weeks ago

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

BCAX

Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer

Jun 5, 2025, 9:34 AM EDT - 4 weeks ago

Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer

Merus N.V. Announces Pricing of Public Offering of Common Shares

Jun 4, 2025, 12:13 AM EDT - 5 weeks ago

Merus N.V. Announces Pricing of Public Offering of Common Shares

Merus N.V. Announces Proposed Public Offering of Common Shares

Jun 3, 2025, 4:05 PM EDT - 5 weeks ago

Merus N.V. Announces Proposed Public Offering of Common Shares

Merus to Present at Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 6 weeks ago

Merus to Present at Upcoming Investor Conferences

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

May 22, 2025, 5:30 PM EDT - 6 weeks ago

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

May 15, 2025, 8:00 AM EDT - 7 weeks ago

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Merus to Present at BofA Securities 2025 Health Care Conference

May 8, 2025, 8:00 AM EDT - 2 months ago

Merus to Present at BofA Securities 2025 Health Care Conference

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

May 7, 2025, 4:11 PM EDT - 2 months ago

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Apr 23, 2025, 10:00 AM EDT - 2 months ago

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Merus: Riding The Bispecific Wave In Oncology

Apr 7, 2025, 4:34 AM EDT - 3 months ago

Merus: Riding The Bispecific Wave In Oncology

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 3 months ago

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Feb 27, 2025, 4:10 PM EST - 4 months ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Feb 18, 2025, 8:00 AM EST - 5 months ago

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Feb 13, 2025, 8:00 AM EST - 5 months ago

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Feb 5, 2025, 5:00 PM EST - 5 months ago

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Jan 20, 2025, 5:08 AM EST - 6 months ago

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Jan 12, 2025, 8:04 PM EST - 6 months ago

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Dec 16, 2024, 4:01 PM EST - 7 months ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Dec 7, 2024, 1:30 AM EST - 7 months ago

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus Scores Its First FDA Approval For Lung Cancer Drug

Dec 5, 2024, 2:49 PM EST - 7 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Dec 4, 2024, 4:55 PM EST - 7 months ago

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

US FDA approves Merus' therapy to treat lung, pancreatic cancers

Dec 4, 2024, 3:48 PM EST - 7 months ago

US FDA approves Merus' therapy to treat lung, pancreatic cancers

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Dec 2, 2024, 8:00 AM EST - 7 months ago

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Dec 1, 2024, 11:05 AM EST - 7 months ago

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 5, 2024, 1:18 PM EST - 8 months ago

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus Receives FDA extension of PDUFA for zenocutuzumab

Nov 5, 2024, 6:30 AM EST - 8 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Oct 31, 2024, 8:08 AM EDT - 8 months ago

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Merus: Great European Oncology Developer, But Properly Valued

Aug 14, 2024, 5:13 PM EDT - 11 months ago

Merus: Great European Oncology Developer, But Properly Valued

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

Jun 3, 2024, 2:30 PM EDT - 1 year ago

Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

Jun 2, 2024, 12:30 PM EDT - 1 year ago

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

Merus Announces Pricing of Upsized Public Offering of Common Shares

May 29, 2024, 9:30 PM EDT - 1 year ago

Merus Announces Pricing of Upsized Public Offering of Common Shares

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

May 28, 2024, 7:00 AM EDT - 1 year ago

Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24, 2024, 1:00 PM EDT - 1 year ago

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

May 23, 2024, 5:00 PM EDT - 1 year ago

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

May 13, 2024, 8:00 AM EDT - 1 year ago

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

May 8, 2024, 4:15 PM EDT - 1 year ago

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

May 6, 2024, 4:05 PM EDT - 1 year ago

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Apr 8, 2024, 12:00 PM EDT - 1 year ago

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

Under-the-radar biotech bets

Apr 3, 2024, 1:47 PM EDT - 1 year ago

Under-the-radar biotech bets

CRNX SNDX XBI

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

Mar 6, 2024, 8:00 AM EST - 1 year ago

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

GILD

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 1, 2024, 3:12 PM EST - 1 year ago

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Feb 28, 2024, 4:15 PM EST - 1 year ago

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

Merus to Participate in Upcoming Investor Conferences

Jan 31, 2024, 8:00 AM EST - 1 year ago

Merus to Participate in Upcoming Investor Conferences

Llamalamb2921
Llamalamb2921 Jul. 8 at 12:35 PM
$MRUS Shareholders here need to look at $PDSB. Market cap is $56M vs nearly $4B for Merus. PDSB is the cleanest play for the lucrative and growing HPV16+ population. Versamune technology also lends itself to other immunotherapy antigens like MUC-1 as well as excellent study results in Universal Flu vaccine hopefully going into human trials soon.
1 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 10:00 AM
BMO Capital updates rating for Merus ( $MRUS ) to Outperform, target set at 91 → 96.
0 · Reply
YasirTrades
YasirTrades Jun. 20 at 12:05 AM
GLMD The risk/reward is insane. Under $2. Cash-rich. No debt. $12+ book. GLP-1 & fibrosis catalysts ahead. No fluff, just facts. $EPIX $ADIL $MRUS $MBOT $SYTA 🚨🚨🚨🚨
0 · Reply
Bionoobbb
Bionoobbb Jun. 14 at 4:11 AM
$MRUS $PDSB Merus 🔹 Target Population: Merus is conducting clinical trials targeting first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). These trials include both HPV-positive and HPV-negative patients. The main therapy is a combination of petosemtamab with Keytruda. 🔹 Current Status: • These trials require patients to be PD-1–naïve (i.e., they must not have received prior anti–PD-1 therapy). • With Keytruda now moving into perioperative use in early-stage disease, a growing portion of patients will receive Keytruda earlier in their treatment journey. • When these patients eventually experience recurrence, they will no longer be eligible for Merus trials due to prior PD-1 exposure. 🔹 Conclusion: ❌ This creates significant near- and long-term negative impact. As Keytruda use expands in early settings, Merus’s addressable patient pool continues to shrink.
1 · Reply
Bionoobbb
Bionoobbb Jun. 13 at 2:00 PM
$PDSB $MRUS @DubK FDA has approved $MRK keytruda in neoadjuvant which will reduce the patient pool for MRUS & $BCAX Smaller Patient Pool • Merck’s Keytruda just got approved for (neoadjuvant use) • Since Keytruda is now approved and proven, doctors may choose it over joining a new trial for an experimental drug. • Result: Fewer patients may join Merus’ trial, making it harder for them to prove their drug works or to sell it later.
0 · Reply
fezziwig2018
fezziwig2018 Jun. 12 at 6:33 PM
“HPV16 & HPV18 are the main high-risk types responsible for both cervical and HNSCC, with HPV16 accounting for 90% of HPV+ OPSCC” https://mdpi.com/1422-0067/23/7/3483 $PDSB targets 16-by far more/more difficult cases of head/neck ca vs $MRUS (strains of 8 pts included in last data omitted) https://www.mdpi.com/1422-0067/23/7/3483
0 · Reply
bmess
bmess Jun. 6 at 7:15 PM
$MRUS not very smart
0 · Reply
OptionsSean
OptionsSean Jun. 6 at 4:56 PM
The market tipped it's hand earlier this week in $MRUS. I'm buying this dip:
1 · Reply
Ontherag
Ontherag Jun. 6 at 2:55 PM
$MRUS Hey Bill, ask KevinHarrington what he thinks. Thanks.
0 · Reply
Llamalamb2921
Llamalamb2921 Jun. 6 at 11:03 AM
$MRUS I strongly recommend that your CEO Bill Lundberg speak with Frank at $PDSB to learn specifically about HPV16+ HNSCC. If not Frank, he can speak to other experts in the field regarding HPV16+ cancers and how they differ from other subsets of HPV+ HNSCC. Bill may need to temper his enthusiasm a bit and give some credit to the people at PDSB with their $65M market cap. He touches his heart a lot and seems to care very much for patients. Would he choose his drug trial for a loved one with an HPV16+ malignancy? Stick to HPV negative tumors Bill. There is enough room in the space for both companies to be successful.
0 · Reply
bmess
bmess Jun. 6 at 2:48 AM
$MRUS y’all are cooked
0 · Reply
DylanGFM
DylanGFM Jun. 6 at 2:42 AM
$MRUS $MRUS public trading started years ago I know but it was a beautiful start. that kind of history with a continued gain over time alone just shows the consistency of this stock versus all the other noise
0 · Reply
Herrfranz
Herrfranz Jun. 5 at 7:32 PM
$MRUS https://youtu.be/4UBXaksMRAQ
0 · Reply
Ontherag
Ontherag Jun. 5 at 7:07 PM
$MRUS Damn, raised 300M just to rerun trials because they have the wrong patient population, frickin disaster
0 · Reply
DonCorleone77
DonCorleone77 Jun. 4 at 7:45 PM
$MRUS $MSFT $NIO $PENN $PYPL Hello Everyone, Just wanted to inform you that I have made posts TODAY with analyst information regarding the stocks below (the number of posts for each stock are in parenthesis). I will also be posting more analyst information for additional stocks later tonight and will post an update when I am done. The easiest way to find the information is via my feed located at: https://x.com/CorleoneDon77 PLEASE FEEL FREE TO RE-SHARE THIS MESSAGE IF THERE ARE ANY OF YOUR FOLLOWERS WHO YOU BELIEVE CAN BENEFIT FROM THIS INFORMATION. Here is a list of the stocks: 1) AAPL (1) 2) CEG (1) 3) CRDO (1) 4) DKNG (1) 5) DOCU (1) 6) HIMS (3) 7) LEU (1) 8) LITE (1) 9) LOW (1) 10) LYFT (1) 11) MRUS (2) 12) MSFT (1) 13) NIO (1) 14) PENN (1) 15) PYPL (1) 16) SNDX (1) 17) SNOW (1) 18) SOC (1) 19) TSLA (1) 20) WFC (4)
0 · Reply
bmess
bmess Jun. 4 at 7:17 PM
$MRUS 25-27$
0 · Reply
kshonstocks
kshonstocks Jun. 4 at 6:02 PM
$MRUS holding key offering level still, will add good close on it
0 · Reply
bmess
bmess Jun. 4 at 3:58 PM
$MRUS yeah this is a scam company that's
0 · Reply
Herrfranz
Herrfranz Jun. 4 at 2:52 PM
$MRUS added 200 shares, now 800 in total. long!
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 4 at 1:15 PM
$MRUS (-7.9% pre) Merus N.V. (MRUS) Prices 5.26M Share Offering at $57/sh https://ooc.bz/l/66879
0 · Reply
m322m
m322m Jun. 4 at 1:01 PM
$MRUS wow I can buy at 57 this is amazing 👌 thank you
0 · Reply
briefingcom
briefingcom Jun. 4 at 11:58 AM
Gapping Down: $ASAN -11.5% $CRWD -6.5% $MRUS -5.5% $ZBIO -5.4%
0 · Reply